The study included 562 hip fracture patients (HF) (age 鈮?#xA0;70 years) admitted to a Danish university hospital. The hip fracture patients were prospectively enrolled in a dedicated hip fracture database. Each hip fracture patient was exactly matched according to age and sex with two controls randomly chosen from a control population of 21,778 subjects who had s-PTH, s-total calcium and s-25(OH)D measured at the Copenhagen General Practitioners Laboratory after referral from their general practitioner. The control group (Con) thus consisted of 1124 subjects.
General 1-year mortality: Con-female 8.4%, Con-male 15.3%, HF-female 24.6%, HF-male 33.3%, p < 0.0001 (log rank).
Con-no SHPT 8.9%, Con-SHPT 16.8%, HF-no SHPT 22.7%, HF-SHPT 34.9%, p < 0.0001 (log rank). The mortality rates were higher for controls with SHPT (OR 2.06, 95%CI: 1.32-3.23), hip fracture patients without SHPT (OR 3.00, 95%CI: 2.14-4.20) and hip fracture patients with SHPT (OR 5.46, 95%CI: 3.32-8.97) compared to the controls without SHPT.
Con 16%, HF 20%, p = 0.09 (Chi-square).
Our study clearly shows that SHPT is significantly associated with mortality in both hip fracture patients and the control group. In the multivariate Cox regression analysis, s-PTH and s-total calcium were both significantly associated with mortality, whereas s-25(OH)D was not associated with mortality in this analysis. Our study furthermore indicates that SHPT is almost equally prevalent amongst the hip fracture patients and the control group.